Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do the beneficial effects of sirolimus-eluting stents extend beyond 1 year?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 508–509 (2005)Cite this article

boxed-textFajadet J et al. (2005) Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. Three-year results of the RAVEL trial. Circulation 111: 1040–1044

Preliminary results of the long-term follow-up of sirolimus-eluting stents indicate that their efficacy is durable and that they are safe, even without long-term antiplatelet therapy, in a select group of patients

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Leon MB et al. (2004) Declining long-term efficacy of vascular brachytherapy for in-stent restenosis: 5-year follow-up from the Gamma-1 randomized trial. Circulation 405 (Suppl 3): S1923

    Google Scholar 

  2. Waksman R et al. (2000) Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 36: 65–68

    Article  CAS  Google Scholar 

  3. Iakovou I et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126–2130

    Article  CAS  Google Scholar 

  4. Orlic D et al. (2004) Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol 43: 1154–1160

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice. I thank Cathy Kennedy, Editorial Coordinator, Center for Interventional Vascular Therapy, Columbia University Medical Center for editorial help.

Author information

Authors and Affiliations

  1. Professor of Medicine at the Columbia University Medical Center, Director of the Center for Interventional Vascular Therapy and Director of the Catheterization Laboratory at Columbia University Medical Center, New York, NY, USA

    Jeffrey W Moses

Authors
  1. Jeffrey W Moses
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey W Moses.

Ethics declarations

Competing interests

JW Moses is a consultant and speaker for Johnson & Johnson, the manufacturer of the Cypher drug-eluting stent, and a speaker for Boston Scientific, the manufacturer of the Taxus drug-eluting stent.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moses, J. Do the beneficial effects of sirolimus-eluting stents extend beyond 1 year?. Nat Rev Cardiol 2, 508–509 (2005). https://doi.org/10.1038/ncpcardio0324

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0324

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing